Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;22(11):3627-3636.
doi: 10.1007/s10461-018-2102-9.

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

Affiliations

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

Christine Tagliaferri Rael et al. AIDS Behav. 2018 Nov.

Abstract

Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City's perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.

Keywords: Barriers; Facilitators; HIV prevention; PrEP; Transgender women; Transwomen.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

All authors declare that they have no conflicts of interest.

Similar articles

Cited by

References

    1. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. [press release]
    1. Kuhns LM, Reisner SL, Mimiaga MJ, Gayles T, Shelendich M, Garofalo R. Correlates of PrEP Indication in a Multi-Site Cohort of Young HIV-Uninfected Transgender Women. AIDS Behav. 2016;20(7):1470–7. - PMC - PubMed
    1. Escudero DJ, Kerr T, Operario D, Socias ME, Sued O, Marshall BD. Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care. 2015;27(5):637–41. - PMC - PubMed
    1. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. The Lancet HIV. 2015;2(12):e512–e9. - PMC - PubMed
    1. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22. - PubMed

Substances